Vaxart Q2 EPS $(0.16) Beats $(0.18) Estimate, Sales $1.36M Beat $80.00K Estimate
Portfolio Pulse from totan@benzinga.com
Vaxart (NASDAQ:VXRT) reported Q2 losses of $(0.16) per share, beating the analyst consensus estimate of $(0.18) by 11.11%. This is a 30.43% increase over losses from the same period last year. The company also reported quarterly sales of $1.36 million, beating the analyst consensus estimate of $80.00 thousand by 1.60K%.
August 04, 2023 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxart's Q2 results beat analyst estimates, with losses per share and sales both outperforming expectations. This could potentially lead to a positive market reaction.
Vaxart's Q2 results exceeded analyst estimates, which is typically a positive signal to the market. The improvement in losses per share and sales compared to the same period last year indicates the company's financial health is improving, which could potentially lead to a positive market reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100